591 related articles for article (PubMed ID: 24996233)
41. Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Kar S; Bhatt DL
Coron Artery Dis; 2012 Sep; 23(6):380-90. PubMed ID: 22728913
[TBL] [Abstract][Full Text] [Related]
42. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Nieto JA; Espada NG; Merino RG; González TC
Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
[TBL] [Abstract][Full Text] [Related]
43. NOACs for thromboprophylaxis in medical patients.
Cohen AA; Rider T
Best Pract Res Clin Haematol; 2013 Jun; 26(2):183-90. PubMed ID: 23953906
[TBL] [Abstract][Full Text] [Related]
44. Novel oral anticoagulants in acute coronary syndrome.
Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
[TBL] [Abstract][Full Text] [Related]
45. Disadvantages of VKA and requirements for novel anticoagulants.
Shameem R; Ansell J
Best Pract Res Clin Haematol; 2013 Jun; 26(2):103-14. PubMed ID: 23953899
[TBL] [Abstract][Full Text] [Related]
46. New oral anticoagulants in the ED setting: a review.
Pollack CV
Am J Emerg Med; 2012 Nov; 30(9):2046-54. PubMed ID: 22795419
[TBL] [Abstract][Full Text] [Related]
47. A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Kasmeridis C; Lip GY; Apostolakis S
Hosp Pract (1995); 2013 Feb; 41(1):61-70. PubMed ID: 23466968
[TBL] [Abstract][Full Text] [Related]
48. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Robertson L; Kesteven P; McCaslin JE
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010957. PubMed ID: 26636644
[TBL] [Abstract][Full Text] [Related]
49. [New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes].
Blanco-Molina A
Rev Clin Esp; 2012 Jan; 212 Suppl 1():3-7. PubMed ID: 23117646
[TBL] [Abstract][Full Text] [Related]
50. The newer direct oral anticoagulants: a practical guide.
Thachil J
Clin Med (Lond); 2014 Apr; 14(2):165-75. PubMed ID: 24715128
[TBL] [Abstract][Full Text] [Related]
51. Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
Friedman RJ
Orthopedics; 2011 Oct; 34(10):795-804. PubMed ID: 21956181
[TBL] [Abstract][Full Text] [Related]
52. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials.
Sardar P; Chatterjee S; Chaudhari S; Lip GY
J Am Geriatr Soc; 2014 May; 62(5):857-64. PubMed ID: 24786913
[TBL] [Abstract][Full Text] [Related]
53. [New anticoagulants: better knowledge, better prescriptions].
Boehlen F; de Moerloose P
Rev Med Suisse; 2012 Jan; 8(324):96-9. PubMed ID: 23185817
[TBL] [Abstract][Full Text] [Related]
54. Newer clinically available antithrombotics and their antidotes.
Lévy S
J Interv Card Electrophysiol; 2014 Sep; 40(3):269-75. PubMed ID: 24934756
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
Hellwig T; Gulseth M
Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
[TBL] [Abstract][Full Text] [Related]
56. New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism.
den Exter PL; Kooiman J; van der Hulle T; Huisman MV
Best Pract Res Clin Haematol; 2013 Jun; 26(2):163-9. PubMed ID: 23953904
[TBL] [Abstract][Full Text] [Related]
57. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Eriksson BI; Quinlan DJ; Eikelboom JW
Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
[TBL] [Abstract][Full Text] [Related]
58. [The new anticoagulants - their role in secondary prevention of thromboembolism after stroke].
Seiffge D; Nedeltchev K; Lyrer P
Ther Umsch; 2012 Sep; 69(9):517-22. PubMed ID: 22923355
[TBL] [Abstract][Full Text] [Related]
59. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
Yates SW
Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819
[TBL] [Abstract][Full Text] [Related]
60. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
